O'Dwyer P J, Mojzisik C M, Hinkle G H, Rousseau M, Olsen J, Tuttle S E, Barth R F, Thurston M O, McCabe D P, Farrar W B
Arch Surg. 1986 Dec;121(12):1391-4. doi: 10.1001/archsurg.1986.01400120037005.
To assess monoclonal antibody (MAb) 17-1A and its F(ab')2 fragment in intraoperative radioimmunodetection and to evaluate further the clinical usefulness of a hand-held gamma-detecting probe (GDP), we injected radiolabeled monoclonal antibody 17-1A three to six days preoperatively or its F(ab')2 fragment two to three days preoperatively into 18 patients with colorectal cancer. Intraoperative GDP counts with tumor-tissue ratios of 1.5:1 or greater were obtained from 15 (75%) of 20 tumor sites, with ratios averaging 2.3:1 for fragments and 3.4:1 for whole antibody. The GDP counts contributed to intraoperative decision making in three patients, either by localization of tumor not identified by inspection or palpation or by mapping margins of resection with histologic confirmation of a local/regional recurrence. These preliminary data demonstrate that probe-directed, intraoperative radioimmunodetection can assist the surgeon in detecting subclinical tumor deposits and thus better evaluate the extent of primary or recurrent colorectal cancers intraoperatively.
为评估单克隆抗体(MAb)17-1A及其F(ab')2片段在术中放射免疫检测中的作用,并进一步评估手持式γ探测仪(GDP)的临床实用性,我们在术前3至6天给18例结直肠癌患者注射放射性标记的单克隆抗体17-1A,或在术前2至3天注射其F(ab')2片段。20个肿瘤部位中有15个(75%)在术中获得了肿瘤组织比为1.5:1或更高的GDP计数,片段的平均比值为2.3:1,完整抗体的平均比值为3.4:1。GDP计数在3例患者的术中决策中发挥了作用,要么是通过定位经检查或触诊未发现的肿瘤,要么是通过绘制切除边缘并经组织学证实局部/区域复发。这些初步数据表明,探针引导的术中放射免疫检测可协助外科医生检测亚临床肿瘤沉积物,从而在术中更好地评估原发性或复发性结直肠癌的范围。